KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q1 2025 value amounting to $6.0 million.

  • Recursion Pharmaceuticals' Asset Writedowns and Impairment rose 541481.48% to $6.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 541481.48%. This contributed to the annual value of $108000.0 for FY2024, which is 9090.91% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Asset Writedowns and Impairment of $6.0 million as of Q1 2025, which was up 541481.48% from $108000.0 recorded in Q1 2024.
  • Recursion Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $6.0 million during Q1 2025, with a 5-year trough of $19000.0 in Q3 2023.
  • In the last 4 years, Recursion Pharmaceuticals' Asset Writedowns and Impairment had a median value of $1.2 million in 2023 and averaged $2.0 million.
  • In the last 5 years, Recursion Pharmaceuticals' Asset Writedowns and Impairment plummeted by 9076.13% in 2024 and then surged by 541481.48% in 2025.
  • Recursion Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $2.8 million in 2022, then crashed by 99.32% to $19000.0 in 2023, then skyrocketed by 468.42% to $108000.0 in 2024, then skyrocketed by 5414.81% to $6.0 million in 2025.
  • Its Asset Writedowns and Impairment was $6.0 million in Q1 2025, compared to $108000.0 in Q1 2024 and $19000.0 in Q3 2023.